Federal Health Minister Greg Hunt will visit Tasmania today to announce new and amended listings to the Pharmaceutical Benefits Scheme.
Subscribe now for unlimited access.
$0/
(min cost $0)
or signup to continue reading
As of November 1, the listings for Tafinlar (dabrafenib) and Mekinist (trametinib) will now include a subsidy for post-surgery treatment for patients with stage IIIB, IIIC and IIID melanoma.
Paediatric patients being treated for relapsing remitting multiple sclerosis are also set to benefit from the amended listings for Gilenya (fingolimod) and Tysabri (natalizumab).
IN OTHER NEWS:
"Through the PBS patients will pay a maximum of $40.30 per script, with concessional people paying just $6.50 per script for these medicines," Mr Hunt said.
Bass Liberal MHR Bridget Archer said she was "very pleased" to welcome the minister to Northern Tasmania.
"Since my election ... I have been speaking with medical professionals across Bass about important issues and have undertaken to raise them with the minister," she said.
Rob Inglis
Rob Inglis is a reporter with The Examiner, covering state and federal politics. He is based in Hobart.
Rob Inglis is a reporter with The Examiner, covering state and federal politics. He is based in Hobart.
